GlobalData on MSN

FDA approves UCB’s Kygevvi for genetic mitochondrial disease

The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme ...

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare an…

This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes ...
MedPage Today on MSN

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...
News Medical

Novel findings may hold promise for children, adults with mitochondrial disorders

Rooted in malfunctions in the tiny power plants that energize our cells, mitochondrial disorders are notoriously complex and variable, with few effective treatments. Now, novel findings in microscopic ...
Daijiworld

FDA approves first drug for TK2 deficiency, giving hope to patients with rare mitochondrial disorder

In a historic medical breakthrough, the US Food and Drug Administration (FDA) has approved KYGEVVI—a combination of ...
The Manual on MSN

Mitochondria and aging: Why HIIT is the game-changer for fitness and longevity

Which exercise is superior for improving mitochondrial functioning? Which exercise results in the most dramatic positive ...

FDA approves first drug for Thymidine Kinase 2 Deficiency: All we know about this very rare mitochondrial disease

A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a ...
BioSpace

UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease

Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease ...
Science Daily

You get your energy from your mom: A new study explains why

Scientists have long wondered why animals get the DNA inside their mitochondria, the cell's energy center, only from their mothers. New research explains why and offers hope for treating mitochondrial ...

FDA Approves KYGEVVI(R) (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and ...

Hirano at Columbia University, an MDA Care Center, to develop a TK2-deficient mouse model, which proved that targeted treatments could restore mitochondrial function. This led to FDA granting ...
PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom ...